Clinical Trial Update: A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients [Phase 2]

View source ↗

Summary

Phase 2a study evaluating cannabidiol as a steroid-sparing therapy in steroid-dependent Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Cannabidiol (CBD) (cannabidiol)

Snippet

Sponsor: Stero Biotechs Ltd. | Conditions: Steroid Dependent Crohn's Disease | Phase 2 | Status: COMPLETED